

## Summary of Product Characteristics

### 1 NAME OF THE MEDICINAL PRODUCT

Seretide 500 Diskus 50 microgram/500 microgram/dose inhalation powder, pre-dispensed.

### 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each single inhalation provides a delivered dose (the dose leaving the mouthpiece) of 47 micrograms of salmeterol (as salmeterol xinafoate) and 460 micrograms of fluticasone propionate. This corresponds to a pre-dispensed dose of 50 micrograms of salmeterol (as salmeterol xinafoate) and 500 micrograms fluticasone propionate.

### 3 PHARMACEUTICAL FORM

Inhalation powder, pre-dispensed.

*Product imported from Bulgaria*

Moulded plastic device containing a foil strip with 60 regularly placed blisters.

### 4 CLINICAL PARTICULARS

As per PA1077/046/003

### 5 PHARMACOLOGICAL PROPERTIES

As per PA1077/046/003

### 6 PHARMACEUTICAL PARTICULARS

#### 6.1 List of excipients

Excipient: Lactose monohydrate (which contains milk proteins).

#### 6.2 Incompatibilities

Not applicable.

#### 6.3 Shelf life

The shelf-life expiry date of this product is the date shown on the container and outer package of the product on the market in the country of origin.

#### 6.4 Special precautions for storage

Do not store above 30°C.

#### 6.5 Nature and contents of container

The inhalation powder is contained in blisters held on a formed PVC coated base, with a peelable foil laminate lid. The strip is contained in a moulded purple plastic device.

The plastic devices are available in cardboard containers, which hold:

1 x 60 dose Diskus

## **6.6 Special precautions for disposal and other handling**

The Diskus releases a powder which is inhaled into the lungs. A dose indicator on the Diskus indicates the number of doses left. For detailed instructions for use see the Patient Information Leaflet.

## **7 PARALLEL PRODUCT AUTHORISATION HOLDER**

Primecrown 2010 Limited  
4/5 Northolt Trading Estate  
Belvue Road  
Northolt  
Middlesex UB5 5QS  
United Kingdom

## **8 PARALLEL PRODUCT AUTHORISATION NUMBER**

PPA1633/063/002

## **9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 25<sup>th</sup> August 2017

## **10 DATE OF REVISION OF THE TEXT**